SLS Stock Surges After-Hours: Sellas Says 'Transformative' Phase 3 AML Results Are Coming This Month

Résumé détaillé

Sellas held $134.7 million in cash at September-end, while Q3 net loss widened to $10.1 million despite a narrower per-share loss.

Shares of Sellas Life Sciences (SLS) surged 17% in after-hours trading on Thursday after the company said that its key leukemia trial results are expected this month, with its CEO pointing to the treatment's potential to become a "transformative" immunotherapy if successful.

SLS stock fell nearly 5% on Thursday to $8.03, with shares on track to post their third straight weekly decline.

See what 10M+ investors are talking about. Get the Stocktwits Daily Rip for what retail is watching right now, free to your inbox

The update is related to the Phase 3 Regal trial of Galinpepimut-S (GPS) in acute myeloid leukemia (AML). The November timeline narrows Sellas' earlier guidance for results in the fourth quarter.

"In our ongoing Phase 3 REGAL trial of GPS, we are focused on completing the final analysis following the announcement of 80th event, and we expect to announce topline primary endpoint results this month," CEO Angelos Stergiou said. "If successful, we believe GPS could be a transformative new immunotherapy for AML patients in second complete remission."

Regal is testing GPS as a maintenance treatment for AML patients who have returned to remission after treatment for a relapse. The study's main goal is to determine whether GPS helps these patients live longer. GPS is licensed from Memorial Sloan Kettering Cancer Center and targets WT1, a protein found in a range of cancers.

Sellas disclosed late last month that the trial had reached its prespecified 80th death, the milestone required to begin its final analysis. This process involves finalizing and reviewing the trial database, revealing treatment assignments and analyzing the results.

Beyond GPS, Sellas is advancing its second leukemia drug, Tambiciclib, or SLS009, with investors looking ahead to fresh trial results and a major medical conference presentation.

The company has enrolled 40 patients in its planned 80-patient Phase 2 study in newly diagnosed AML, up from 28 disclosed in August.

Début de l'article, extrait de Yahoo Finance. Pour lire la suite, ouvrez l'article chez le média.